Physician profile
Harish Bhaskar
NPI 1750506705
$9,897.83
in general payments reported to CMS, 2019-2025
23 companies · $411 in 2025
The $411 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,415 · 2020: $3,771 · 2021: $137 · 2022: $93.72 · 2023: $1,222 · 2024: $848 · 2025: $411.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,391 · Education: $89.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,390.73 |
| Education | $89.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $5,214.72 | 2019-2024 | |
| Pulmonx Corporation | $1,722.78 | 2019-2025 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Zephyr Endobronchial Valve |
| Inari Medical, INC. | $748.34 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Actelion Pharmaceuticals US, INC. | $410.80 | 2023-2025 | Uptravi, Opsumit, Opsynvi |
| United Therapeutics Corporation | $409.63 | 2019-2024 | Tyvaso, Orenitram |
| Genentech USA, INC. | $284.37 | 2019 | |
| Insmed, INC. | $206.08 | 2019-2025 | Arikayce |
| Boehringer Ingelheim Pharmaceuticals, INC. | $195.57 | 2019-2023 | Stiolto Respimat |
| Inspire Medical Systems, INC. | $127.50 | 2023 | Inspire |
| Verona Pharma, INC. | $125.00 | 2025 | Ohtuvayre |
| Mylan Specialty L.P. | $68.31 | 2019 | |
| Glaxosmithkline, LLC. | $66.63 | 2019-2025 | Nucala |
| Ambu INC. | $46.53 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $42.35 | 2019 | |
| Grifols USA, LLC | $40.15 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $39.77 | 2019 | |
| Philips North America LLC | $32.58 | 2022-2023 | |
| Allergan, INC. | $29.17 | 2019 | |
| Novartis Pharmaceuticals Corporation | $26.79 | 2019 | |
| Jazz Pharmaceuticals INC. | $18.06 | 2019 | |
| Csl Behring | $18.02 | 2019 | |
| Vapotherm INC | $13.77 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $10.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harish Bhaskar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.